\
&
Contact us
\
&
Contact us
Published on | 4 years ago
ProgrammesThe Commission has updated on 30 November 2021 the pre-draft of the Annotated Model Grant Agreement (of all programmes, not only Horizon Europe).
This version has been updated with corporate annotations of Articles 1-6 (i.e. annotations for all programmes). These annotations explain notably personnel costs daily rate calculation with single calculation over the reporting period.
The annotations to the other articles remain those of the pre-draft AGA for HE as previously published on 23 July 2021. These will be updated later on by further batch(es) of corporate annotations for all programmes. We will keep you informed about this process.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Digital, Industry & Space Climate, Energy, Mobility AI Continent
The Horizon Europe project AI-BOOST has launched 4 specific Generative AI challenges to drive significant research progress in different areas: Challenge 1: GenAI-Based Natural Language Mission Generator for Autonomous Robots in Agriculture (deadline: 25 August 2026) Challenge 2: Agentic AI for Automated CAD Generation and Autonomous Simulation... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
